Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	33D2176119	10/21/2024
Name of Provider or Supplier	**Street Address, City, State**	
Statcare Urgent And Walk-In Medical Care	80-10 Northern Blvd, Jackson Heights, NY	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	Based on a proficiency testing (PT) desk review survey performed on October 21, 2024, the laboratory was found to be out of compliance based on the following CONDITION LEVEL DEFICIENCIES: D2016 - 42 C.F.R. 493.803 Condition: Successful participation. D6000 - 42 C.F.R. 493.1403 Condition: Laboratory Director, moderate complexity.
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of Centers for Medicare & Medicaid Services (CMS) Proficiency Testing (PT) Certification and Survey Provider Enhanced Reporting system (CASPER 0155D) and American Proficiency Institute (API) PT summary reports, the

	laboratory failed to successfully participate in the CMS approved PT program for two out of three consecutive testing events in the Diagnostic Immunology subspecialty for Syphilis Serology test analyte in 2024; the General Immunology subspecialty for the Anti-HIV (Anti-Human Immunodeficiency Virus Antibody), HBsAg (Hepatitis B Surface Antigen), and Anti-HBc (Anti-Hepatitis B Core Antibody) test analytes in 2024; the Routine Chemistry subspecialty for the ALT (Alanine Aminotransferase) (SGPT) (Serum Glutamic-Pyruvic Transaminase), Albumin, Alk Phos (Alkaline Phosphatase), AST (Aspartate Aminotransferase) (SGOT) (Serum Glutamic-Oxaloacetic Transaminase), Bili (Bilirubin), Total, CA (Calcium), Total, CL (Chloride), Cholesterol, Total, Cholesterol, HDL (High-Density Lipoprotein), Creatinine, Glucose (Non-Waived), Iron, Total, LDH (Lactate Dehydrogenase), Total, MG (Magnesium), K (Potassium), NA (Sodium), Total Protein, Trigl (Triglycerides), BUN (Blood Urea Nitrogen), and Uric Acid test analytes in 2024; as well as the Endocrinology subspecialty for the Free TY (Thyroxine), Triiodothyronine, and TSH (Thyroid Stimulating Hormone) test analytes in 2024, resulting in unsuccessful performance. Refer to D2074, D2084, D2096, and D2107.
D2074	SYPHILIS SEROLOGY CFR(s): 493.835(e) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on CMS PT CASPER 0155D and API PT summary reports from 2024, the laboratory failed to achieve satisfactory performance (80% or greater) for two of three consecutive testing events in the Diagnostic Immunology subspecialty for the Syphilis Serology test analyte. FINDINGS: 1. A review of the CASPER 155 report revealed the following unsatisfactory scores: Syphilis Serology Test Analyte: 2024 First Event = 0% 2024 Second Event = 0% 2. A review of the proficiency testing scores from API (2024) confirmed the above findings.
D2084	GENERAL IMMUNOLOGY CFR(s): 493.837(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on CMS PT CASPER 0155D and API PT summary reports from 2024, the laboratory failed to achieve satisfactory performance (80% or greater) for two of three consecutive testing events in the General Immunology subspecialty for the Anti-HIV, HBsAg, and Anti-HBc test analytes. FINDINGS: 1. A review of the CASPER 155 report revealed the following unsatisfactory scores: General Immunology Subspecialty: 2024 First Event = 0% 2024 Second Event = 0% Anti-HIV Test Analyte: 2024 First Event = 0% 2024 Second Event = 0% HBsAg Test Analyte: 2024 First Event = 0% 2024 Second Event = 0% Anti-HBc Test Analyte: 2024 First Event = 0% 2024 Second Event = 0% 2. A review of the proficiency testing scores from API (2024) confirmed the above findings.

D2096	ROUTINE CHEMISTRY CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on CMS PT CASPER 0155D and API PT summary reports from 2024, the laboratory failed to achieve satisfactory performance (80% or greater) for two of three consecutive testing events in the Routine Chemistry subspecialty for the ALT (SGPT), Albumin, Alk Phos, AST (SGOT), Bili, Total, CA, Total, CL, Cholesterol, Total, Cholesterol, HDL, Creatinine, Glucose (Non-Waived), Iron, Total, LDH, Total, MG, K, NA, Total Protein, Trigl, BUN, and Uric Acid test analyte. FINDINGS: 1. A review of the CASPER 155 report revealed the following unsatisfactory scores: Routine Chemistry Subspecialty: 2024 Second Event = 0% 2024 Third Event = 0% ALT (SGPT) Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Albumin Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Alk Phos Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% AST (SGOT) Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Bili, Total Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% CA, Total Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% CL Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Cholesterol, Total Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Cholesterol, HDL Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Creatinine Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Glucose (Non-Waived) Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Iron, Total Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% LDH, Total Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% MG Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% K Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% NA Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Total Protein Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Trigl Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% BUN Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% Uric Acid Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% 2. A review of the proficiency testing scores from API (2024) confirmed the above findings.
D2107	ENDOCRINOLOGY CFR(s): 493.843(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on CMS PT CASPER 0155D and API PT summary reports from 2024, the laboratory failed to achieve satisfactory performance (80% or greater) for two of three consecutive testing events in the Endocrinology subspecialty for the Free TY, Triiodothyronine, and TSH test analytes. FINDINGS: 1. A review of the CASPER 155 report revealed the following unsatisfactory scores: Endocrinology Subspecialty: 2024 Second Event = 0% 2024 Third Event = 0% Free TY Test Analyte: 2024 Second

	Event = 0% 2024 Third Event = 0% Triiodothyronine Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% TSH Test Analyte: 2024 Second Event = 0% 2024 Third Event = 0% 2. A review of the proficiency testing scores from API (2024) confirmed the above findings.
D6000	MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on review of CMS PT CASPER 0155D and API PT summary reports from 2024, the laboratory director (LD) failed to provide overall management and direction of the laboratory services. Refer to D2016.
D6016	LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on review of CMS PT CASPER 0155D and API PT 2024-1, 2024-2, and 2024-3 summary reports, the LD failed to ensure successful participation in an HHS approved proficiency testing program. Refer to D2074, D2084, D2096, and 2107.